Association of IL36RN mutation with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis

Psoriasis

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations

J Dermatol.

Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, Bieber T, Schön MP, Hüffmeier U, Mössner R

doi: 10.1111/

Psoriasis

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis

JAMA Dermatol.

Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C, British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium.

doi: 10.1001/jamadermatol.2019.1783.

Psoriasis

Evaluation of the Frequency of "Not Relevant" Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis

JAMA Dermatol.

Barbieri JS, Shin DB, Syed MN, Takeshita J, Gelfand JM

doi: 10.1001/jamadermatol.2019.4659.

Psoriasis

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

JAMA Dermatol.

van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ

doi: 10.1001/jamadermatol.

T Cells

A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional psoriasis skin

J Allergy Clin Immunol.

Gallais Sérézal I, Hoffer E, Ignatov B, Martini E, Zitti B, Ehrström M, Eidsmo L

doi: 10.1016/j.jaci.

Psoriasis

Clinical and trichoscopic features in various forms of scalp psoriasis

J Eur Acad Dermatol Venereol

Bruni F, Alessandrini A, Starace M, Orlando G, Piraccini BM

doi: 10.1111/jdv.17354

Psoriasis

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

Br J Dermatol

Iskandar IYK, Lunt M, Thorneloe RJ, Cordingley L, Griffiths CEM, Ashcroft DM, British Association of Dermatologists Biologics, Immunomodulators Register, Psoriasis Stratification to Optimise Relevant Therapy Study Groups.

doi: 10.1111/bjd.20577

AcnePsoriasis

Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

Br J Dermatol

Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM

doi: 10.1111/bjd.20568

Psoriasis

Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients

JAMA Dermatol.

Bruins FM, Bronckers IMGJ, Groenewoud HMM, van de Kerkhof PCM, de Jong EMGJ, Seyger MMB

doi: 10.1001/jamadermatol.2019.3717.

Related content

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis

Evaluation of the Frequency of "Not Relevant" Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional psoriasis skin

Clinical and trichoscopic features in various forms of scalp psoriasis

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients